Does the media refer more to NVCR or MMED?

In the previous week, MiniMed Group had 8 more articles in the media than NovoCure. MarketBeat recorded 9 mentions for MiniMed Group and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat MiniMed Group's score of 0.37 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, NVCR or TFX?

NovoCure has higher earnings, but lower revenue than Teleflex. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.53 -$136.23M -$1.30 N/A Teleflex $1.99B 2.64 -$905.64M -$23.29 N/A

Is NVCR or TFX more profitable?

NovoCure has a net margin of -21.25% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Teleflex -39.67% 11.93% 5.44%

Does the media refer more to NVCR or TFX?

In the previous week, Teleflex had 2 more articles in the media than NovoCure. MarketBeat recorded 3 mentions for Teleflex and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat Teleflex's score of 0.00 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teleflex 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, NVCR or HAE?

Haemonetics has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.53 -$136.23M -$1.30 N/A Haemonetics $1.33B 4.07 $97.31M $2.04 58.47

Is NVCR or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to NovoCure's net margin of -21.25%. Haemonetics' return on equity of 27.55% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Haemonetics 7.12% 27.55% 9.65%

Does the media refer more to NVCR or HAE?

In the previous week, Haemonetics had 17 more articles in the media than NovoCure. MarketBeat recorded 18 mentions for Haemonetics and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat Haemonetics' score of 0.49 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 7 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, NVCR or ITGR?

Integer has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.53 -$136.23M -$1.30 N/A Integer $1.85B 2.32 $102.81M $3.66 34.60

Is NVCR or ITGR more profitable?

Integer has a net margin of 6.97% compared to NovoCure's net margin of -21.25%. Integer's return on equity of 12.79% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Integer 6.97% 12.79% 6.48%

Does the media favor NVCR or ITGR?

In the previous week, Integer had 4 more articles in the media than NovoCure. MarketBeat recorded 5 mentions for Integer and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat Integer's score of 0.21 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integer 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, LIVN or NVCR?

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.01 -$242.47M $3.38 22.46 NovoCure $655.35M 2.53 -$136.23M -$1.30 N/A

Is LIVN or NVCR more profitable?

LivaNova has a net margin of 12.82% compared to NovoCure's net margin of -21.25%. LivaNova's return on equity of 16.35% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% NovoCure -21.25% -44.00% -15.85%

Does the media prefer LIVN or NVCR?

In the previous week, LivaNova had 4 more articles in the media than NovoCure. MarketBeat recorded 5 mentions for LivaNova and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat LivaNova's score of 0.56 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NovoCure (NVCR) Competitors

$14.58 +0.36 (+2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$14.58 -0.01 (-0.03%)

As of 07:30 PM Eastern

Compare

NVCR vs. MMED, TFX, HAE, ITGR, and LIVN

Should you buy NovoCure stock or one of its competitors? NovoCure's main competitors and comparable companies include MiniMed Group (MMED), Teleflex (TFX), Haemonetics (HAE), Integer (ITGR), and LivaNova (LIVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NovoCure compare to MiniMed Group?

NovoCure (NASDAQ:NVCR) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

NovoCure has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.53	-$136.23M	-$1.30	N/A
MiniMed Group	$3.10B	1.80	-$333M	-$0.68	N/A

NovoCure currently has a consensus target price of $21.20, suggesting a potential upside of 49.09%. MiniMed Group has a consensus target price of $24.00, suggesting a potential upside of 21.21%. Given NovoCure's higher probable upside, equities research analysts plainly believe NovoCure is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
MiniMed Group	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, MiniMed Group had 8 more articles in the media than NovoCure. MarketBeat recorded 9 mentions for MiniMed Group and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat MiniMed Group's score of 0.37 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiniMed Group has a net margin of 0.00% compared to NovoCure's net margin of -21.25%. MiniMed Group's return on equity of 0.00% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
MiniMed Group	N/A	N/A	N/A

84.6% of NovoCure shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Comparatively, 0.0% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MiniMed Group beats NovoCure on 8 of the 15 factors compared between the two stocks.

How does NovoCure compare to Teleflex?

NovoCure (NASDAQ:NVCR) and Teleflex (NYSE:TFX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Teleflex had 2 more articles in the media than NovoCure. MarketBeat recorded 3 mentions for Teleflex and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat Teleflex's score of 0.00 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teleflex	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Teleflex has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

NovoCure has a net margin of -21.25% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Teleflex	-39.67%	11.93%	5.44%

NovoCure currently has a consensus target price of $21.20, indicating a potential upside of 49.09%. Teleflex has a consensus target price of $155.20, indicating a potential upside of 24.80%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Teleflex	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.67

84.6% of NovoCure shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 6.6% of NovoCure shares are held by insiders. Comparatively, 0.7% of Teleflex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NovoCure has higher earnings, but lower revenue than Teleflex. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.53	-$136.23M	-$1.30	N/A
Teleflex	$1.99B	2.64	-$905.64M	-$23.29	N/A

Summary

Teleflex beats NovoCure on 10 of the 17 factors compared between the two stocks.

How does NovoCure compare to Haemonetics?

NovoCure (NASDAQ:NVCR) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Haemonetics has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.53	-$136.23M	-$1.30	N/A
Haemonetics	$1.33B	4.07	$97.31M	$2.04	58.47

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 6.6% of NovoCure shares are owned by company insiders. Comparatively, 2.1% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Haemonetics had 17 more articles in the media than NovoCure. MarketBeat recorded 18 mentions for Haemonetics and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat Haemonetics' score of 0.49 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	7 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Haemonetics has a net margin of 7.12% compared to NovoCure's net margin of -21.25%. Haemonetics' return on equity of 27.55% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Haemonetics	7.12%	27.55%	9.65%

NovoCure presently has a consensus target price of $21.20, suggesting a potential upside of 49.09%. Haemonetics has a consensus target price of $102.00, suggesting a potential downside of 14.49%. Given NovoCure's higher probable upside, equities analysts plainly believe NovoCure is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

Haemonetics beats NovoCure on 13 of the 17 factors compared between the two stocks.

How does NovoCure compare to Integer?

NovoCure (NASDAQ:NVCR) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Integer has a net margin of 6.97% compared to NovoCure's net margin of -21.25%. Integer's return on equity of 12.79% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Integer	6.97%	12.79%	6.48%

NovoCure has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Integer has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

NovoCure presently has a consensus price target of $21.20, indicating a potential upside of 49.09%. Integer has a consensus price target of $109.86, indicating a potential downside of 13.25%. Given NovoCure's stronger consensus rating and higher probable upside, analysts plainly believe NovoCure is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Integer has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.53	-$136.23M	-$1.30	N/A
Integer	$1.85B	2.32	$102.81M	$3.66	34.60

In the previous week, Integer had 4 more articles in the media than NovoCure. MarketBeat recorded 5 mentions for Integer and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat Integer's score of 0.21 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integer	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.6% of NovoCure shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 6.6% of NovoCure shares are held by insiders. Comparatively, 1.1% of Integer shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Integer beats NovoCure on 9 of the 16 factors compared between the two stocks.

How does NovoCure compare to LivaNova?

LivaNova (NASDAQ:LIVN) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

LivaNova currently has a consensus price target of $87.75, indicating a potential upside of 15.60%. NovoCure has a consensus price target of $21.20, indicating a potential upside of 49.09%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.01	-$242.47M	$3.38	22.46
NovoCure	$655.35M	2.53	-$136.23M	-$1.30	N/A

In the previous week, LivaNova had 4 more articles in the media than NovoCure. MarketBeat recorded 5 mentions for LivaNova and 1 mentions for NovoCure. NovoCure's average media sentiment score of 0.88 beat LivaNova's score of 0.56 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 6.6% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

LivaNova has a net margin of 12.82% compared to NovoCure's net margin of -21.25%. LivaNova's return on equity of 16.35% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
NovoCure	-21.25%	-44.00%	-15.85%

LivaNova has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Summary

LivaNova beats NovoCure on 12 of the 17 factors compared between the two stocks.

Get NovoCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCR vs. The Competition

Export

Metric	NovoCure	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.66B	$5.44B	$7.20B	$13.28B
Dividend Yield	N/A	1.78%	2.53%	16.36%
P/E Ratio	N/A	25.53	274.76	26.18
Price / Sales	2.59	71.11	632.15	98.25
Price / Cash	N/A	32.10	76.82	53.72
Price / Book	4.80	5.93	11.21	6.34
Net Income	-$136.23M	$146.18M	$3.50B	$381.90M
7 Day Performance	-2.41%	-0.17%	-0.84%	-1.39%
1 Month Performance	-6.72%	-3.15%	-5.42%	-4.31%
1 Year Performance	1.74%	2.91%	4.38%	-0.35%

NovoCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCR NovoCure	3.0187 of 5 stars	$14.58 +2.5%	$21.20 +45.4%	-0.9%	$1.66B	$655.35M	N/A	1,605
MMED MiniMed Group	2.4523 of 5 stars	$20.16 +2.3%	$24.14 +19.8%	N/A	$5.54B	$3.10B	N/A	2,800	Analyst Forecast Options Volume High Trading Volume
TFX Teleflex	4.1386 of 5 stars	$125.40 +1.0%	$155.20 +23.8%	-3.2%	$5.26B	$1.99B	N/A	15,500
HAE Haemonetics	2.3956 of 5 stars	$104.85 +0.2%	$99.78 -4.8%	+133.9%	$4.76B	$1.33B	51.40	3,009	Trending News Analyst Forecast
ITGR Integer	1.9942 of 5 stars	$126.62 +0.1%	$109.86 -13.2%	+20.2%	$4.30B	$1.85B	34.60	11,000	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCR) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NovoCure (NVCR) Competitors

NVCR vs. MMED, TFX, HAE, ITGR, and LIVN

How does NovoCure compare to MiniMed Group?

Summary

How does NovoCure compare to Teleflex?

Summary

How does NovoCure compare to Haemonetics?

Summary

How does NovoCure compare to Integer?

Summary

How does NovoCure compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCR vs. The Competition

NovoCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NovoCure (NVCR) Competitors

NVCR vs. MMED, TFX, HAE, ITGR, and LIVN

How does NovoCure compare to MiniMed Group?

Which has better earnings and valuation, NVCR or MMED?

Do analysts prefer NVCR or MMED?

Does the media refer more to NVCR or MMED?

Is NVCR or MMED more profitable?

Do insiders & institutionals hold more shares of NVCR or MMED?

Summary

How does NovoCure compare to Teleflex?

Does the media refer more to NVCR or TFX?

Which has more risk and volatility, NVCR or TFX?

Is NVCR or TFX more profitable?

Do analysts prefer NVCR or TFX?

Do institutionals & insiders hold more shares of NVCR or TFX?

Which has preferable earnings & valuation, NVCR or TFX?

Summary

How does NovoCure compare to Haemonetics?

Which has better earnings & valuation, NVCR or HAE?

Do institutionals and insiders have more ownership in NVCR or HAE?

Does the media refer more to NVCR or HAE?

Which has more risk & volatility, NVCR or HAE?

Is NVCR or HAE more profitable?

Do analysts prefer NVCR or HAE?

Summary

How does NovoCure compare to Integer?

Is NVCR or ITGR more profitable?

Which has more volatility & risk, NVCR or ITGR?

Do analysts prefer NVCR or ITGR?

Which has stronger earnings & valuation, NVCR or ITGR?

Does the media favor NVCR or ITGR?

Do institutionals & insiders believe in NVCR or ITGR?

Summary

How does NovoCure compare to LivaNova?

Do analysts rate LIVN or NVCR?

Which has better earnings and valuation, LIVN or NVCR?

Does the media prefer LIVN or NVCR?

Do institutionals & insiders hold more shares of LIVN or NVCR?

Is LIVN or NVCR more profitable?

Which has more volatility & risk, LIVN or NVCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCR vs. The Competition

NovoCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools